Afya (AFYA) Stock Sees Fair Value Cut As Analysts Weigh Yduqs Merger Risks

Afya’s updated fair value moved to US$15.22 from US$17.62, a reduction of about 13.6% that puts fresh focus on where the stock might fit in your portfolio. Recent analyst research pairs this lower price target range with more cautious views on execution, interest rates, and the merger process, even as some ratings shift higher. Read on to see what is driving this evolving Afya narrative and how you can keep track of the next round of changes.

Stay updated as the Fair Value for Afya shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Afya.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Several firms have shifted to more constructive ratings on Afya, with Citi moving to Buy from Neutral and JPMorgan to Overweight from Neutral, while Bradesco BBI raised its stance to Outperform from Underperform.

• Citi highlights what it calls resilient undergraduate trends and points to expected net sales growth supported by medical and other health related courses, which it sees as an anchor for Afya’s education portfolio.

• JPMorgan cites the planned merger with Yduqs and points to projected R$1.8b in synergies in its research, and describes the combined entity as its preferred education company in Latin America.

• Even with lower price targets, firms like Bradesco BBI at US$17, JPMorgan at US$17.50 and Citi at US$12 still frame Afya within coverage lists that focus on companies they view as relatively well positioned in Brazilian education.

🐻 Bearish Takeaways

• Morgan Stanley stays cautious on Afya’s seat maturation and structural trends in the market and trims its target to US$12.60 from US$15, even as it moves the rating up to Equal Weight from Underweight.

• Both Citi and JPMorgan cut their Afya price targets alongside wider reductions across Brazilian education stocks after factoring in a higher cost of capital and a higher for longer interest rate curve.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

See how Afya’s fair value stacks up across multiple valuation models — not just analyst targets.

How This Changes the Fair Value For Afya

• Fair value for Afya moved to US$15.22 from US$17.62, a reduction of about 13.6%.

• The assumed long term R$ revenue growth rate changed to 5.80% from 6.13%.

• The R$ net profit margin assumption moved to 18.74% from 22.09%.

• The future P/E multiple is now 10.94x compared with 9.71x previously.

• The discount rate used in the model shifted to 10.49% from 10.77%.